Tools
Tools
Garg, Pankaj 
ORCID: https://orcid.org/0000-0002-5483-169X, Dakshi, Ahmed, Assadi, Hosamadin ORCID: https://orcid.org/0000-0002-6143-8095, Swift, Andrew J., Naveed, Umna, Fent, Graham, Lewis, Nigel, Rogers, Dominic, Charalampopoulos, Athanasios and Al-Mohammad, Abdallah
(2021)
Characterisation of the patients with suspected heart failure: experience from the SHEAF registry.
Open Heart, 8.
ISSN 2053-3624
Preview |
PDF (Published_Version)
- Published Version
Available under License Creative Commons Attribution Non-commercial. Download (2MB) | Preview |
Abstract
Objectives To characterise and risk-stratify patients presenting to a heart failure (HF) clinic according to the National Institute for health and Care Excellence (NICE) algorithm. Methods This is an observational study of prospectively collected data in the Sheffield HEArt Failure registry of consecutive patients with suspected HF between April 2012 and January 2020. Outcome was defined as all-cause mortality. Results 6144 patients were enrolled: 71% had HF and 29% had no HF. Patients with N-terminal pro-brain-type natriuretic peptide (NT-proBNP) >2000 pg/mL were more likely to have HF than those with NT-proBNP of 400–2000 pg/mL (92% vs 64%, respectively). Frequency of HF phenotypes include: HF with preserved ejection fraction (HFpEF) (33%), HF with reduced ejection fraction (HFrEF) (29%), HF due to valvular heart disease (4%), HF due to pulmonary hypertension (5%) and HF due to right ventricular systolic dysfunction (1%). There were 1485 (24%) deaths over a maximum follow-up of 6 years. The death rate was higher in HF versus no HF (11.49 vs 7.29 per 100 patient-years follow-up, p<0.0001). Patients with HF and an NT-proBNP >2000 pg/mL had lower survival than those with NT-proBNP 400–2000 pg/mL (3.8 years vs 5 years, p<0.0001). Propensity matched survival curves were comparable between HFpEF and HFrEF (p=0.88). Conclusion Our findings support the use by NICE’s HF diagnostic algorithm of tiered triage of patients with suspected HF based on their NT-proBNP levels. The two pathways yielded distinctive groups of patients with varied diagnoses and prognosis. HFpEF is the most frequent diagnosis, with its challenges of poor prognosis and paucity of therapeutic options.
| Item Type: | Article |
|---|---|
| Additional Information: | Funding information: AJS is supported by Wellcome Trust (AS: 205188/Z/16/Z). PG is supported by the Academy of Sciences Starter Grant (PG: SGL018/1100). |
| Uncontrolled Keywords: | cardiology and cardiovascular medicine ,/dk/atira/pure/subjectarea/asjc/2700/2705 |
| Faculty \ School: | Faculty of Medicine and Health Sciences > Norwich Medical School Faculty of Science > School of Biological Sciences |
| UEA Research Groups: | Faculty of Medicine and Health Sciences > Research Centres > Metabolic Health |
| Related URLs: | |
| Depositing User: | LivePure Connector |
| Date Deposited: | 12 Apr 2021 23:49 |
| Last Modified: | 19 Oct 2023 02:56 |
| URI: | https://ueaeprints.uea.ac.uk/id/eprint/79687 |
| DOI: | 10.1136/openhrt-2020-001448 |
Downloads
Downloads per month over past year
Actions (login required)
 |
View Item |